Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

Table 2 MRI lesion volumes at Week 96

Mean change from baseline (SD)	Delayed treatment	Peginterferon beta-1a
Mean change from baseline (SD)	Delayed treatment	Every 4 weeks	Every 2 weeks
Patients with available data, n	391	389	406
T2 hyperintense lesion volume, cm³	0.617 (2.2341)	0.362 (2.6841)^†	-0.231 (1.6103)^a*
T1 hypointense lesion volume, cm³	0.869 (1.6907)	0.914 (2.4103)	0.478 (1.2417)*
Gd + lesion volume, cm³	-0.135 (0.5478)	-0.164 (0.8676)	-0.113 (0.4460)

Gd+ gadolinium-enhancing lesions; SD standard deviation *p < 0.0001, ^† p = 0.046 versus delayed treatment by Wilcoxon rank-sum test ^a n = 407

ISSN: 1471-2377